RecruitingNCT05002556
AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Sponsor
Association Francaise d'Urologie
Enrollment
8,000 participants
Start Date
Feb 21, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary molecular test (biomarker) prior to their resection (biopsy) diagnosis or recurrence,
- AND adult (equal to or \> 18 years old),
- AND affiliated with a social security scheme in France,
- AND whose monitoring will be carried out at the recruiting center.
Exclusion Criteria4
- Patient being monitored for a non-urothelial bladder tumor
- Patient refusing follow-up
- Opposition to participation in the study
- Adult protected by law
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05002556
Related Trials
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT0720622553 locations
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT0663742313 locations
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT0571084810 locations
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT065036143 locations
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
NCT062456039 locations